AbbVie Inc (ABBV)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$1.88
-2.59%
HEALTHCARE · Cap: $9.38M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 600633% more annual revenue ($64.39B vs $10.72M). ABBV leads profitability with a 9.8% profit margin vs -41.9%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
WOK
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for WOK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
19.1% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while WOK is a growth play — different risk/reward profiles.
WOK carries more volatility with a beta of 1.75 — expect wider price swings.
WOK is growing revenue faster at 19.1% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 35/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a pioneering player in the medical technology sector, dedicated to the advancement of healthcare through the research, development, and commercialization of innovative medical devices. The company's diverse portfolio is designed to tackle pressing challenges in global healthcare, underscoring its commitment to improving patient outcomes. With a strong emphasis on quality, innovation, and responsiveness to market demands, WORK is ideally positioned for sustainable growth, making it an attractive investment opportunity for institutional investors seeking exposure to transformational healthcare solutions in an evolving industry landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?